Nandrolone phenylpropionate

NPP has been used mainly in the treatment of advanced breast cancer in women and as an adjunct therapy for the treatment of senile or postmenopausal osteoporosis in women. However, nandrolone esters have more recently been proposed for the treatment of androgen deficiency in men due to favorable properties including their high ratio of anabolic to androgenic effects and consequent much lower risk of prostate enlargement, prostate cancer, and scalp hair loss relative to testosterone. Available forms NPP is or has been available 25 mg/mL and 50 mg/mL formulations in oil solution for intramuscular injection. ==Non-medical uses==

NPP is used for physique- and performance-enhancing purposes by competitive athletes, bodybuilders, and powerlifters. This is in part due to the high ratio of anabolic to androgenic effect of nandrolone and its weak propensity for androgenic and estrogenic side effects. ==Side effects==

The most common side effects of NPP consist of virilization (masculinization) in women, including symptoms such as acne, hirsutism (increased body/facial hair growth), hoarseness of the voice, and voice deepening. However, relative to most other AAS, NPP has a greatly reduced propensity for virilization and such side effects are relatively uncommon at recommended dosages. At higher dosages and/or with long-term treatment they make increase in incidence and magnitude however. A variety of uncommon and rare side effects may also occur. == Interactions ==

Antiestrogens like aromatase inhibitors (e.g., anastrozole) and selective estrogen receptor modulators (e.g., tamoxifen, raloxifene) can interfere with and prevent the estrogenic effects of NPP. ==Pharmacology==

Pharmacodynamics , the active form of NPP. NPP is a nandrolone ester, or a prodrug of nandrolone. Relative to testosterone, NPP has enhanced anabolic effects and reduced androgenic effects. ==Chemistry==

Nandrolone phenylpropionate, or nandrolone 17β-phenylpropionate, is a synthetic estrane steroid and a derivative of testosterone. It is an androgen ester; specifically, it is the C17β phenylpropionate ester of nandrolone (19-nortestosterone), which itself is the 19-demethylated analogue of testosterone. ==History==

NPP was first described in 1957 and was introduced for medical use in 1959. It was initially used for a wide variety of indications, but starting in the 1970s its use became more restricted and its main uses became the treatment of breast cancer and osteoporosis in women. Today, NPP is scarcely available. The drug was the first form of nandrolone to be introduced, and was followed by nandrolone decanoate in 1962, which has been more widely used in comparison. ==Society and culture==

Generic names Nandrolone phenylpropionate is the generic name of the drug and its while nandrolone phenpropionate is its . Nandrolone decanoate, conversely, is one of the few AAS that remains available for medical use in this country. == References ==